Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atovaquone/proguanil · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Atovaquone/proguanil HCL | EXPERIMENTAL | Atovaquone/proguanil HCL |
| Atovaquone 750 mg | ACTIVE_COMPARATOR | Atovaquone 750 mg |
| Atovaquone 1500 mg | ACTIVE_COMPARATOR | Atovaquone 1500 mg |
| Name | Type | Description |
|---|---|---|
| Atovaquone/proguanil HCL | DRUG | Atovaquone/proguanil HCL |
| Atovaquone | DRUG | Atovaquone |
Inclusion Criteria: * Healthy as defined as being free from clinically significant illness or disease as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, vital sign, laboratory tests and ECG. * Japanese healthy mal...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 4 | PHASE3 | Tafenoquine, GSK3772701, Mosquirix, GSK4425689A |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
Atovaquone/proguanil is used for malaria. It is an antimalarial small molecule combination developed by GSK plc, which trades under the ticker GSK. The program is in Phase 1 clinical development, and the malaria indication places it in the infectious disease therapeutic area.
Atovaquone/proguanil is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor behind the clinical program for this antimalarial combination, including the Phase 1 study conducted in Japan.
Atovaquone/proguanil is in Phase 1 clinical development. It is an investigational antimalarial combination and is not described as approved. The program has one completed Phase 1 trial, with no active trials currently listed.
Atovaquone/proguanil has been studied in one completed Phase 1 trial, NCT01858831, titled Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension. That trial enrolled 30 healthy male volunteers aged 20 years and older in Japan and was active controlled.